Abstract Safe mucosal delivery of live respiratory vaccines remains challenging. We developed CIVSA1, an NS1-truncated H3N2 canine influenza live attenuated vaccine (LAIV), and evaluated sublingual administration as a non-respiratory mucosal route. In mice, high-dose sublingual CIVSA1 produced no recoverable infectious virus or histopathologic injury in lungs, whereas intranasal dosing produced pulmonary replication.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Danbi
Contact Danbi, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack